| Ytd | 40.30% | |
| 1y | 26.06% |
| Open | Prev Close | 16.64 | Low | High | Mkt Cap | 458.80M | |||
| Vol | 0.00 | Avg Vol | 359.47K | EPS | -10.91 | P/E | -1.53 | Forward P/E | -17.04 |
| Beta | 1.20 | Short Ratio | 0.19 | Inst. Own | 8.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 01-13 | Earning | N/A | 50-d Avg | 18.01 | 200-d Avg | 14.71 | 1yr Est | 0.00 |
CBIO News
WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compa
WALTHAM, Mass. , July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Comp
Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-sta
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compa
WALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compa
WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compa
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compa
Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Resident
WALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compan
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NS
WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compan
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compan
Stocks traded mixed, with Dow down 0.1% but NASDAQ up 1.06%. Chevron reported mixed Q1 results. Espe
US stocks traded higher, with the Nasdaq up 1%. Dow up 0.05%, Nasdaq up 1.13%, S&P 500 up 0.58%.
ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody
WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Comp
Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl
Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Comp
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) has been given an average rating of "Buy"
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Comp
Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compa
WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Compa
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, includi
Gainers Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) shares jumped 153% to $3.24 after the co